Registry for identifying risk factors of esophageal cancer
Official title: Esophageal Cancer Risk Registry
Run by University of Pittsburgh · NCT00260585 · Data updated 2026-11-12
This study is trying to find out if certain blood and tissue markers can help identify people at risk for esophageal cancer by looking at their medical history and samples.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 7000 (estimated) |
| Sponsor | University of Pittsburgh Academic / other |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Status | Recruiting |
| Started | June 1999 |
| Main results expected | December 2050 |
| Study ends | December 2050 |
| Registry record updated | April 14, 2026 |
| Trial ID | NCT00260585 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with known or suspected esophageal malignancies, Barrett's metaplasia, symptomatic GERD, achalasia, or hiatal hernia.
✕Probably not a fit
Patients with elevated pre-operative bloodwork or specific coagulation issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify blood and tissue markers that indicate risk factors for esophageal cancer development and progression. Patients with esophageal disorders will provide medical history, blood, and tissue samples, which will be analyzed for genetic and behavioral risk factors. The study seeks to enhance early detection and prevention strategies for esophageal cancer by examining changes in genetic material and proteins. Participants will undergo questionnaires and sample collection during routine clinical visits.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and prevention strategies for esophageal cancer, potentially increasing survival rates.
How similar studies have gone: Other studies have shown promise in identifying genetic markers for cancer risk, suggesting that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Known or suspected esophageal or gastroesophageal junction malignancy * Known Barrett's metaplasia * Clinical management of symptomatic gastroesophageal reflux disease (GERD) * Achalasia * Hiatal hernia Exclusion Criteria: * Elevated pre-operative bloodwork will not have the additional biopsies taken. * Platelet count less than 150,000, partial thromboplastin time (PTT) of 50 or above, and/or International Normalized Ratio (INR) of 1.8 or above will not have the additional biopsies taken.
Where it's running
-
Department of Cardiothoracic Surgery
Pittsburgh, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: James D. Luketich, MD — Department of Cardiothoracic Surgery
- Study coordinator: Julie A Ward, BSN
- Email: wardj@upmc.edu
- Phone: 412-647-8583
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing Botox and surgery for stomach drainage during esophagectomy
This study is testing whether Botox injections can help people who have had esophagus surgery manage delayed stomach emptying just as well as surgery can.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.